Study Enrollment

Your details will not be published or shared.

Clinical Trial

(Savara) A Phase III, randomized, double-blind, placebo-controlled study of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus lung infection in cystic fibrosis patients

Eligibility Criteria

  • Adults and minors six years old and older Documented diagnosis of Cystic Fibrosis Positive diagnosis of MRSA infection

Contact Information

    Kathleen T. McKie, MD

    (706) 721-2635